Etelcalcetide inhibits the progression of left atrial volume index compared to alfacalcidol in hemodialysis patients.

ABSTRACT:

Introduction

Increased left atrial (LA) size is a risk factor for cardiovascular events and all-cause mortality. It is closely related to left ventricular hypertrophy and chronic volume overload, both of which are common in hemodialysis. Calcimimetic treatment with Etelcalcetide (ETL) previously showed an inhibitory effect on left ventricular mass index (LVMI) progression in this population.

Methods

This is a post-hoc analysis of the EtECAR-HD trial, where 62 patients were randomized to ETL or alfacalcidol (ALFA) for one year. LA volume index (LAVI) was measured using cardiac magnetic resonance imaging. The aim of the study was to investigate whether ETL was associated with a change of LAVI.

Results

Median baseline levels of LAVI were 40 ml/m² (31,54 IQR) in the ETL-

SUBMITTER: Dorr K 

PROVIDER: S-EPMC10664324 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature